ForceDelivery Mechanosensitive proteins as a pathway to mechano-targeted drug delivery
- Coordinator
- Universitat Linz, Austria
- Runs
- 1 September 2024 to 31 August 2026
- Status
- Running
- EU funding
- €184k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101109118
What the project is doing
In the project's own words, from its summary on CORDIS.
Biophysical research over the last two decades has revealed that an impressive number of mechanical signals are key regulators of cell behavior. So far, the focus has been on understanding fundamental mechanosensing and transduction mechanisms in health and disease. As increasing numbers of molecular players and signalling pathways are identified, the time has come to utilize this knowledge for diagnosing and treating diseases where mechanical processes play a role.
In this proposal, I aim to target integrins to deliver reporter molecules and drugs to cells with a distinct mechanical phenotype. Integrins are transmembrane receptors through which cells can sense, transmit and discriminate biomechanical forces. During cell adhesion and migration, integrins engage with specific ligands in the extracellular matrix and undergo integrin recycling through continuous endo- and exocytosis.
This known endocytic pathway, integrin clustering during adhesion and overexpression in disease states has made integrins a prime target for drug delivery. However, the chemical and physical factors governing integrin-mediated uptake of drugs and their intracellular fate are unknown. I propose to utilize molecular force sensor (MFS) technology to deconvolute the key factors in integrin-mediated drug delivery. Using rational protein design, a series of coiled coil MFSs with distinct chemical (charge and hydrophobicity) and physical (mechanical and thermal stability) properties will be produced.
The molecular constructs will be appended with the integrin-targeting RGD motif, a fluorescent protein to investigate the intracellular fate and an actin-binding protein as a model drug that may potentially interfere with the cytoskeleton architecture. This MFS-based drug delivery system will enlighten the pivotal factors of integrin-mediated delivery, provide a diagnostic assay for discriminating cells based on their mechanical phenotype and open up the road towards mechano-targeted drug delivery.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitat Linz | Linz | Austria | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI